Sourcing · Regulatory · continued

Prescription requirements and telehealth models posts 61–90

Sourcing › Regulatory FDA compounding research use only MHRA

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

BramleyTL2Member11 Dec 2025#61

customs_ledger, post #24: Picking up post #21: that is the part I would want checked first. Prescription requirements and telehealth models has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet. Go to post

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

Posted with less confidence than the sentence structure implies.

0 likes in reply to #24 8mo

r.chukwuTL212 Dec 2025#62

sleep_log, post #10: I think the prescription requirements and telehealth models question is answerable and has not been answered, which is a more optimistic position than most of this thread. Go to post

The failure mode on prescription requirements and telehealth models is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

29 likes in reply to #10 8mo

c.niemelTL3Regular12 Dec 2025 · edited#63

Clear enough that I do not think I have a follow-up, which is unusual.

14 likes 8mo

n.dziedzicTL213 Dec 2025#64

Post #61 answers the question as asked. The question underneath it is different.

I would call the community position on prescription requirements and telehealth models likely rather than established, and I would be comfortable defending that hedge.

5 likes 7mo

o.cousineauTL3Regular13 Dec 2025#65

cannula_trace, post #19: Building on post #18 rather than restating it. The documentation on prescription requirements and telehealth models is better than this thread and I say that as someone who has posted in the thread. Go to post

Worth separating two things that post #61 runs together.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

This is the sort of thing the wiki should carry and currently does not.

0 likes in reply to #19 7mo

s.ferreiraTL214 Dec 2025#66

Summarising the prescription requirements and telehealth models thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.

21 likes 7mo

e.okaforTL214 Dec 2025#67

Scheduling and prescription status are separate questions and the answer to one does not imply the other.

It cost nothing to check and would have cost something not to.

9 likes 7mo

n.vogelTL215 Dec 2025#68

Since prescription requirements and telehealth models keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

2 likes 7mo

h.karlsenTL215 Dec 2025#69

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

30 likes 7mo

l.trevinoTL216 Dec 2025 · edited#70

s.karlsen_rph, post #26: Post #24 answers the question as asked. The question underneath it is different. Offering a way to settle prescription requirements and telehealth models rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision. Go to post

Picking up post #69: that is the part I would want checked first.

Agreed on prescription requirements and telehealth models, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.

15 likes in reply to #26 7mo

no.silvaTL216 Dec 2025#71

i.boateng, post #14: Coming back to post #12, because the follow-up matters more than the original answer. If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category. Go to post

Practical experience of prescription requirements and telehealth models, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.

1 like in reply to #14 7mo

np_gilmoreTL317 Dec 2025#72

Collapsed as off-topic by two members at trust level 3 or above

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

I would be glad to be shown a cleaner way of putting this.

s.dialloTL217 Dec 2025 · edited#73

Post #71 is right about the mechanism and I think understates the practical bit.

A definition problem is doing most of the work in this prescription requirements and telehealth models discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.

15 likes 7mo

peak_purityTL3Analytical chemist18 Dec 2025#74

Coming back to post #70, because the follow-up matters more than the original answer.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

30 likes 7mo

m.onwukaTL218 Dec 2025#75

f.weiss, post #23: On post #21 — agreed on the reasoning, with one qualification. An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence. Anyone who has looked at this more carefully, please correct the record. Go to post

What I would check first on prescription requirements and telehealth models is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.

0 likes in reply to #23 7mo

owen.bradyTL4 Moderator19 Dec 2025#76

Nothing to add, except that this is the answer I would give if asked.

3 likes 7mo

r.laurentTL219 Dec 2025#77

Confirming post #75 from a second method, which matters more than confirming it from a second person.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

10 likes 7mo

mira.patelTL4 Admin19 Dec 2025#78

My understanding of prescription requirements and telehealth models is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.

23 likes 7mo

l.solbergTL220 Dec 2025#79

Collapsed as off-topic by two members at trust level 3 or above

The arithmetic in post #77 is right; the assumption feeding it is the part to check.

Scheduling and prescription status are separate questions and the answer to one does not imply the other.

e.verhoevenTL220 Dec 2025#80

dietitian_hollis, post #17: Prescription requirements and telehealth models: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this. Go to post

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

1 like in reply to #17 7mo

maintenance_modeTL3Regular21 Dec 2025#81

k.haddad, post #57: Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported. I am confident about the direction and much less about the magnitude. Go to post

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

17 likes in reply to #57 7mo

au.pereiraTL221 Dec 2025#82

a.stephanopoulos, post #39: Where I would push back on the prescription requirements and telehealth models consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed. Go to post

Before the thread moves on from prescription requirements and telehealth models — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

7 likes in reply to #39 7mo

logbook_erinTL3Regular22 Dec 2025#83

Everything in post #80 holds. The case it does not cover is the one I have.

Two things can be true about prescription requirements and telehealth models at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.

0 likes 7mo

a.ilungaTL222 Dec 2025#84

Narrowing post #83, because the general version has more than one answer.

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

0 likes 7mo

coldchain_liuTL323 Dec 2025#85

Collapsed as off-topic by two members at trust level 3 or above

Post #83 put the caveat in the right place and I want to underline it.

For anyone finding this later: the short answer on prescription requirements and telehealth models is that it depends on one thing, and the rest of the thread is people identifying which thing.

m.nascimentoTL223 Dec 2025#86

j.teixeira, post #32: Scheduling and prescription status are separate questions and the answer to one does not imply the other. Go to post

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

4 likes in reply to #32 7mo

physio_marchettiTL2Physiotherapist24 Dec 2025#87

Practical note on prescription requirements and telehealth models: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.

0 likes 7mo

n.oseiTL224 Dec 2025#88

That is a cleaner way of putting what I was circling around.

25 likes 7mo

v.szaboTL3Analytical chemist25 Dec 2025#89

maintenance_mode, post #81: Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post. Go to post

Where I part company with post #87, and it is a narrow parting.

Answering the prescription requirements and telehealth models question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.

7 likes in reply to #81 7mo

h.vargaTL225 Dec 2025 · edited#90

Post #87 is the version of this I will quote in future. One addition.

Scheduling and prescription status are separate questions and the answer to one does not imply the other.

One of those cases where knowing the mechanism does not help the decision.

1 like 7mo